Cargando…

Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread

Biomarkers are urgently required to support current histological staging to provide additional accuracy in stratifying colorectal cancer (CRC) patients according to risk of spread to properly assign adjuvant chemotherapy after surgery. Chemotherapy is given to patients with stage III to reduce the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirana, Chandra, Peng, Lifeng, Miller, Rose, Keating, John P., Glenn, Corinne, Shi, Hongjun, Jordan, T. William, Maddern, Guy J., Stubbs, Richard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341757/
https://www.ncbi.nlm.nih.gov/pubmed/30679934
http://dx.doi.org/10.1186/s12014-019-9223-7
_version_ 1783389009708318720
author Kirana, Chandra
Peng, Lifeng
Miller, Rose
Keating, John P.
Glenn, Corinne
Shi, Hongjun
Jordan, T. William
Maddern, Guy J.
Stubbs, Richard S.
author_facet Kirana, Chandra
Peng, Lifeng
Miller, Rose
Keating, John P.
Glenn, Corinne
Shi, Hongjun
Jordan, T. William
Maddern, Guy J.
Stubbs, Richard S.
author_sort Kirana, Chandra
collection PubMed
description Biomarkers are urgently required to support current histological staging to provide additional accuracy in stratifying colorectal cancer (CRC) patients according to risk of spread to properly assign adjuvant chemotherapy after surgery. Chemotherapy is given to patients with stage III to reduce the risk of recurrence but is controversial in stage II patients. Up to 25% of stage II patients will relapse within 5 years after tumor removal and when this occurs cure is seldom possible. The aim of this study was to identify protein biomarkers to stratify risk of spread of CRC patients. Laser micro-dissection was used to isolate cancer cells from primary colorectal tumors of stage II patients which did or did not metastasize within 5 years after surgical resection. Protein expression differences between two groups of tumors were profiled by 2D-DIGE with saturation CyDye labeling and identified using MALDI-TOF mass spectrometry. Evaluation of protein candidates was conducted using tissue micro array (TMA) immunohistochemistry on 125 colorectal tumor tissue samples of different stages. A total of 55 differentially expressed proteins were identified. Ten protein biomarkers were chosen based on p value and ratio between non metastasized and metastazised groups and evaluated on 125 tissues using TMA immunohistochemistry. Expression of HLAB, protein 14-3-3β, LTBP3, ADAMTS2, JAG2 and NME2 on tumour cells was significantly associated with clinical parameters related to tumour progression, invasion and metastasis. Kaplan–Meier survival curve showed strong expression of six proteins was associated with good CRC specific survival. Expression of HLAB, ADAMTS2, LTBP3, JAG2 and NME2 on tumour cells, was associated with tumour progression and invasion, metastasis and CRC specific survival may serve as potential biomarkers to stratify CRC patients into low and high risk of tumour metastasis. Combined methods of laser microdissection, 2D DIGE with saturation labelling and MALDI-TOF MS proved to be resourceful techniques capable of identifying protein biomarkers to predict risk of spread of CRC to liver.
format Online
Article
Text
id pubmed-6341757
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63417572019-01-24 Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread Kirana, Chandra Peng, Lifeng Miller, Rose Keating, John P. Glenn, Corinne Shi, Hongjun Jordan, T. William Maddern, Guy J. Stubbs, Richard S. Clin Proteomics Research Biomarkers are urgently required to support current histological staging to provide additional accuracy in stratifying colorectal cancer (CRC) patients according to risk of spread to properly assign adjuvant chemotherapy after surgery. Chemotherapy is given to patients with stage III to reduce the risk of recurrence but is controversial in stage II patients. Up to 25% of stage II patients will relapse within 5 years after tumor removal and when this occurs cure is seldom possible. The aim of this study was to identify protein biomarkers to stratify risk of spread of CRC patients. Laser micro-dissection was used to isolate cancer cells from primary colorectal tumors of stage II patients which did or did not metastasize within 5 years after surgical resection. Protein expression differences between two groups of tumors were profiled by 2D-DIGE with saturation CyDye labeling and identified using MALDI-TOF mass spectrometry. Evaluation of protein candidates was conducted using tissue micro array (TMA) immunohistochemistry on 125 colorectal tumor tissue samples of different stages. A total of 55 differentially expressed proteins were identified. Ten protein biomarkers were chosen based on p value and ratio between non metastasized and metastazised groups and evaluated on 125 tissues using TMA immunohistochemistry. Expression of HLAB, protein 14-3-3β, LTBP3, ADAMTS2, JAG2 and NME2 on tumour cells was significantly associated with clinical parameters related to tumour progression, invasion and metastasis. Kaplan–Meier survival curve showed strong expression of six proteins was associated with good CRC specific survival. Expression of HLAB, ADAMTS2, LTBP3, JAG2 and NME2 on tumour cells, was associated with tumour progression and invasion, metastasis and CRC specific survival may serve as potential biomarkers to stratify CRC patients into low and high risk of tumour metastasis. Combined methods of laser microdissection, 2D DIGE with saturation labelling and MALDI-TOF MS proved to be resourceful techniques capable of identifying protein biomarkers to predict risk of spread of CRC to liver. BioMed Central 2019-01-22 /pmc/articles/PMC6341757/ /pubmed/30679934 http://dx.doi.org/10.1186/s12014-019-9223-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kirana, Chandra
Peng, Lifeng
Miller, Rose
Keating, John P.
Glenn, Corinne
Shi, Hongjun
Jordan, T. William
Maddern, Guy J.
Stubbs, Richard S.
Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread
title Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread
title_full Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread
title_fullStr Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread
title_full_unstemmed Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread
title_short Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread
title_sort combination of laser microdissection, 2d-dige and maldi-tof ms to identify protein biomarkers to predict colorectal cancer spread
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341757/
https://www.ncbi.nlm.nih.gov/pubmed/30679934
http://dx.doi.org/10.1186/s12014-019-9223-7
work_keys_str_mv AT kiranachandra combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT penglifeng combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT millerrose combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT keatingjohnp combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT glenncorinne combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT shihongjun combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT jordantwilliam combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT maddernguyj combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread
AT stubbsrichards combinationoflasermicrodissection2ddigeandmalditofmstoidentifyproteinbiomarkerstopredictcolorectalcancerspread